127 related articles for article (PubMed ID: 19559572)
1. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study.
Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Degner D; Buchkremer G; Gastpar M; Möller HJ; Riedel M
Eur Psychiatry; 2009 Dec; 24(8):501-6. PubMed ID: 19559572
[TBL] [Abstract][Full Text] [Related]
2. Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients.
Jäger M; Riedel M; Obermeier M; Schennach-Wolff R; Seemüller F; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Bottlender R; Möller HJ
Schizophr Res; 2010 May; 118(1-3):183-8. PubMed ID: 20181461
[TBL] [Abstract][Full Text] [Related]
3. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia.
Lin CH; Lin HS; Lin SC; Kuo CC; Wang FC; Huang YH
Acta Psychiatr Scand; 2018 Feb; 137(2):98-108. PubMed ID: 29280500
[TBL] [Abstract][Full Text] [Related]
4. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
5. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
Schennach-Wolff R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
J Psychiatr Res; 2011 Dec; 45(12):1639-47. PubMed ID: 21862035
[TBL] [Abstract][Full Text] [Related]
6. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
[TBL] [Abstract][Full Text] [Related]
7. An early improvement threshold to predict response and remission in first-episode schizophrenia.
Schennach-Wolff R; Seemüller FH; Mayr A; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Häfner H; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Riedel M
Br J Psychiatry; 2010 Jun; 196(6):460-6. PubMed ID: 20513856
[TBL] [Abstract][Full Text] [Related]
8. Prediction of symptom remission in schizophrenia during inpatient treatment.
Jäger M; Riedel M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Bottlender R; Strauss A; Möller HJ
World J Biol Psychiatry; 2009; 10(4 Pt 2):426-34. PubMed ID: 17853260
[TBL] [Abstract][Full Text] [Related]
9. One-year functional outcomes of naturalistically treated patients with schizophrenia.
Spellmann I; Riedel M; Schennach R; Seemüller F; Obermeier M; Musil R; Jäger M; Schmauß M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ
Psychiatry Res; 2012 Aug; 198(3):378-85. PubMed ID: 22421065
[TBL] [Abstract][Full Text] [Related]
10. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
[TBL] [Abstract][Full Text] [Related]
11. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM
Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985
[TBL] [Abstract][Full Text] [Related]
12. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.
Masand P; O'Gorman C; Mandel FS
Schizophr Res; 2011 Mar; 126(1-3):174-83. PubMed ID: 21185155
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine.
Lin CH; Chou LS; Lin CH; Hsu CY; Chen YS; Lane HY
J Clin Psychiatry; 2007 Oct; 68(10):1522-7. PubMed ID: 17960966
[TBL] [Abstract][Full Text] [Related]
14. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods.
Chen L; Ascher-Svanum H; Stauffer V; Kinon BJ; Kollack-Walker S; Ruberg S
Schizophr Res; 2009 Aug; 113(1):34-40. PubMed ID: 19564097
[TBL] [Abstract][Full Text] [Related]
15. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
O'Gorman C; Kapur S; Kolluri S; Kane J
Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
[TBL] [Abstract][Full Text] [Related]
16. Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.
Subeesh V; Maheswari E; Singh H; Saraswathy GR; Reddy N; Chiranjeevi P
Int J Psychiatry Clin Pract; 2020 Sep; 24(3):309-314. PubMed ID: 32338556
[No Abstract] [Full Text] [Related]
17. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review.
Samara MT; Leucht C; Leeflang MM; Anghelescu IG; Chung YC; Crespo-Facorro B; Elkis H; Hatta K; Giegling I; Kane JM; Kayo M; Lambert M; Lin CH; Möller HJ; Pelayo-Terán JM; Riedel M; Rujescu D; Schimmelmann BG; Serretti A; Correll CU; Leucht S
Am J Psychiatry; 2015 Jul; 172(7):617-29. PubMed ID: 26046338
[TBL] [Abstract][Full Text] [Related]
18. Optimizing early prediction for antipsychotic response in schizophrenia.
Chang YC; Lane HY; Yang KH; Huang CL
J Clin Psychopharmacol; 2006 Dec; 26(6):554-9. PubMed ID: 17110810
[TBL] [Abstract][Full Text] [Related]
19. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
20. Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.
Kumagai F; Suzuki T; Fleischhacker WW; Yasui-Furukori N; Mimura M; Uchida H
J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
